Respiratory syncytial virus (RSV) can be life-threatening for newborns. More than a common cold, RSV can lead to severe infections, including pneumonia. In the U.S., RSV is the leading cause of infant hospitalization. While there is currently no approved vaccination to prevent RSV infections, scientists are researching an investigational vaccine.
- Must be infants younger than one year old
- Must have been carried in the womb for 29 or more weeks
- Must be entering their first RSV season
- Will receive compensation for study-related time
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for your child.
You can talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Submit your information
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.